LOI Deadline: July 10, 2020
Link to RFA

The Alzheimer’s Drug Discovery Foundation is inviting LOIs for its Neuroimaging and CSF Biomarker Development Program.

Specifically, this RFP is focused on developing novel PET ligands for clinical use; supporting novel CSF biomarkers; and validating established MRI approaches in larger cohorts. Novel biomarkers of neuroinflammation and synaptic integrity are considered a high priority. Other target areas of interest include neuronal loss, vascular injury and blood-brain barrier integrity, mitochondria and metabolic function, protein misfolding/proteostasis, oxidative stress, white matter changes, and other novel targets supported by compelling biological rationale and connection to disease. ADDF has limited interest in CSF measures of amyloid and tau. Grants of up to $600,000 will be awarded in support of the advancement of neuroimaging and CSF biomarkers that can do one or more of the following:

Demonstrate Target Engagement for Novel Therapeutics — Biomarkers that can serve as direct measures of target engagement for novel drugs in clinical development. Priority will be given to projects advancing biomarkers that can be used as specific companion biomarkers for therapies currently in the development pipeline and identification of such therapies strengthens an application.

Detect Signs of Disease Earlier and Monitor Progression — Programs developing sensitive biomarkers that can detect disease earlier than currently available biomarkers. This includes biomarkers that can predict and monitor conversion from cognitively healthy to mild cognitive impairment (MCI), or MCI to Alzheimer’s disease. ADDF also seeks prognostic markers that can predict rates of cognitive decline.

More Accurately Diagnose and Distinguish Between Dementia Subtypes — Many types of dementia can present with similar clinical features, and patients often show overlapping pathologies. At present, it is challenging to distinguish between dementia subtypes and proteinopathies. Biomarkers that can distinguish between subtypes and stratify patients in clinical trials are a high priority.

Letters of Intent are due July 10. Upon review, selected applicants will be invited to submit a full proposal by August 7, 2020.

Eligible applicants include researchers and clinicians at academic medical centers, universities, nonprofits, and biotechnology companies worldwide. Existing companies and new spinouts also are eligible, and industry partnerships are strongly encouraged.

See the Alzheimer’s Drug Discovery Foundation website for complete program details, eligibility criteria, and a link to the application portal.

Deadline: July 1, 2020
Link to RFP

The CHARGE Syndrome Foundation is dedicated to promoting high-quality clinical and scientific research on the cause and treatment of CHARGE syndrome, a genetic, extremely complex syndrome involving extensive medical and physical difficulties that differ from child to child.

To that end, the foundation is welcoming applications for its research grants program. Two types of grants will be awarded through the program:

Basic Science Research — Grants of up to $50,000 will be awarded in support of new biomedical research into the etiology, genetic, and molecular mechanisms and treatment of CHARGE syndrome; or for new research on the medical diagnosis and treatment of CHARGE syndrome. Both established and new investigators are encouraged to apply. 

Clinical Research Grant Program — Grants of up to $25,000 will be awarded in support of clinical research on the treatment, intervention, prevention, and support of individuals with medical, health, and behavioral issues, and their families. Both established and new investigators are encouraged to apply.

Preference will be given to projects that include investigators who are new to CHARGE research and to projects with clear potential to lead to future funding from other agencies.

See the CHARGE Syndrome Foundation website for complete program guidelines, application instructions, and information about previous recipients.

Deadline: July 1, 2020
Link to complete RFP

Launched in 1922, the mission of the Sigma Theta Tau International Honor Society of Nursing is to develop nurse-leaders and support nursing research.

To that end, the organization welcomes applications for the Sigma/American Nurses Credentialing Center (ANCC) Evidence-Based Practice Implementation Grant. A single grant of $20,000 over eighteen months will be awarded to encourage nurses in a clinical setting to apply evidence to practice and evaluate the effects on patient outcomes. The proposed project may be inter-professional in design but must be nurse-led.

To be eligible, the principal project lead must be a registered nurse (or country equivalent) with current license and have at least a master’s in nursing (or country equivalent), as well as be a member of either the American Nurses Association or Sigma.

See the Sigma Theta Tau International Honor Society of Nursing website for complete program guidelines and application instructions.